Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT05497557
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT05489614
- Locations
- 🇺🇸
Inland Empire Clinical Trials, LLC, Rialto, California, United States
🇺🇸CRSCA HC LLC, dba Creekside Post Acute, Yucaipa, California, United States
🇺🇸Clinical Pharmacology Of Miami, LLC, Miami, Florida, United States
Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 155
- Registration Number
- NCT05430854
- Locations
- 🇬🇷
Kianous Stavros, Thessaloníki, Greece
🇬🇷Athens General Hospital 'G Gennimatas, Athens, Greece
🇬🇷University General Hospital of Larissa, Larisa, Greece
Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT05406115
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Translational Clinical Research LLC, Aventura, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 769
- Registration Number
- NCT05398445
- Locations
- 🇵🇱
Dermatologiczna Praktyka Lekarska Michal Torz Dermaceum Centrum Badan Klinicznych, Wroclaw, Poland
🇱🇻Smite Aija practice in dermatology and venerology, Talsi, Latvia
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Other: Lp(a) Screening
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 39480
- Registration Number
- NCT05378529
- Locations
- 🇲🇽
Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada SC, Culiacan, Sinaloa, Mexico
🇲🇽Fundacion Cardiovascular de Aguascalientes AC, Aguascalientes, Mexico
🇲🇽Procliniq Investigación Clínica Sa de Cv, Ciudad de México, Mexico
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT05368103
- Locations
- 🇨🇦
The Centre for Clinical Trials, Oakville, Ontario, Canada
🇨🇦Innovaderm Research, Montréal, Quebec, Canada
🇨🇦Centre de Recherche Saint-Louis (Quebec), Quebec, Canada
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 340
- Registration Number
- NCT05361395
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 146
- Registration Number
- NCT05327491
- Locations
- 🇺🇸
Labcorp Clinical Research Unit - Dallas, Dallas, Texas, United States
🇺🇸Miami Research Associates LLC - Main Campus / Late Phase, South Miami, Florida, United States
🇺🇸Labcorp Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 260
- Registration Number
- NCT05325866
- Locations
- 🇦🇹
Landeskrankenhaus Salzburg, Salzburg, Austria
🇫🇷Gustave Roussy, Villejuif, France
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland